Many people are surprised to learn that the International Agency for Research on Cancer (IARC) classifies combined estrogen-progestogen oral contraceptives as Group 1 carcinogens. That classification means there is strong scientific evidence that they can cause cancer under certain conditions. It does not mean they carry the same level of real-world risk as every other Group 1 agent.

Research has found that long-term use of combined oral contraceptives is associated with an increased risk of breast, cervical, and liver cancer in some women. At the same time, these medications have also been shown to reduce the risk of ovarian and endometrial cancers.

This is an important reminder that health decisions are rarely black and white. Every medication has potential benefits and potential risks, and those risks can vary based on factors such as age, length of use, family history, and overall health.

The goal isn't to create fear. It's to encourage informed decisions. Understanding both the benefits and the potential risks allows you to have more meaningful conversations with your healthcare provider and choose what is best for your individual situation.

This post is for educational purposes only and is not medical advice.